本帖最后由 老马 于 2013-3-13 13:43 编辑 , g4 q8 N) t. ]. f3 S
( x* e4 f- q) O* Q( T& r$ \
健择(吉西他滨)+顺铂+阿瓦斯汀1 P& `8 \" @$ A6 a( h: `7 q
Gemzar +Cisplatin + Avastin4 O/ X7 X5 b- u) O4 m, Y. W) ]
http://annonc.oxfordjournals.org/content/21/9/1804.full
% ~3 q4 K# B# l+ {1 Y5 VOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ J6 K6 w, p: n3 E; O ?6 ]) t2 UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ; L$ }- _+ ^* O6 q8 F
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 E8 V8 Q1 W$ q! x6 K' `( R6 E
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 980)
7 y, ?& t( x3 K4 A% A
华为网盘附件:
7 r- ^+ f0 N! T4 R【华为网盘】ava.JPG
9 y' e% F& F$ H6 X% t, k# Z |